Biomolecule classification technology developer Arago Bioscience emerged out of Oxford in April this year and has now been backed by two of the university's funds.
Arago Bioscience, a UK-based biomolecule classification technology spinout from University of Oxford, has obtained an undisclosed sum from university venture fund Oxford Science Innovation and co-investment vehicle University of Oxford Innovation Fund (UOIF) IV.
UOIF is managed by Parkwalk Advisors, the fund management arm of commercialisation firm IP Group, to provide spinouts from the university with matching capital from external sources.
Founded in April 2018, Arago Bioscience has devised a biotechnology that detects and quantifies molecules so clients can perform imaging, localisation and classification of the molecules without having to physically label them.
The approach will be primarily marketed towards the pharmaceutical, biomedical and research sectors for its ability to characterise molecular interactions.
Arago Bioscience commercialises research from Oxford’s chemistry department conducted in the lab of Philipp Kukura, which focuses on finding optical methodologies to study molecular structures and dynamics.
